trending Market Intelligence /marketintelligence/en/news-insights/trending/4IhSwQS2MwWJc1f9P0UUlg2 content esgSubNav
In This List

GSK's president of US pharmaceuticals to step down; replacement named

Case Study

Identifying PPE Suppliers During the Pandemic

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective


GSK's president of US pharmaceuticals to step down; replacement named

GlaxoSmithKline PLC said Jack Bailey is stepping down as president of U.S. pharmaceuticals at the end of 2019.

Bailey, who has been with GlaxoSmithKline since 2009, will remain as a consultant to the company on the U.S. external environment until 2020.

Meanwhile, the company named Maya Martinez-Davis as Bailey's successor. Martinez-Davis is currently the regional president of EMD Serono Inc.'s Latin America region.

EMD Serono is the Rockland, Mass.-based biopharmaceutical unit of Germany's MERCK KGaA which develops therapies for cancer and neurodegenerative diseases.

Martinez-Davis is set to join GlaxoSmithKline in mid-September and will begin her responsibility as head of the company's U.S. pharmaceuticals business beginning Jan. 1, 2020.